1,136 research outputs found
Evaluation of Bacillus anthracis extractable antigen for testing anthrax immunity
ABSTRACTThree extractable Bacillus anthracis cell-wall-associated antigens were evaluated for potential use as skin testing agents, and as possible candidates for in-vitro diagnosis of anthrax immunity. Anthraxin and a partially purified extractable antigen (EAP) were produced from avirulent B. anthracis strain 34F2 (Sterne). The thermoextractable antigen used for the Ascoli reaction was obtained commercially. Guineapigs were immunised and boosted several times subcutaneously with the Sterne live veterinary anthrax vaccine. Four weeks after the last booster dose, animals were skin-tested with the three antigens. Serum antibody levels were also determined by ELISA, and the in-vitro T-cell response was evaluated by [3H]-thymidine incorporation. EAP was the most active antigen in both the serological and cellular reactions. EAP also elicited a distinct positive skin reaction in animals immunised with B. anthracis. The data obtained in this preliminary study indicated that extractable cell-wall antigens obtained from the vegetative form of B. anthracis may be used for skin tests and in-vitro testing of specific humoral and cell-mediated anthrax immunity
Autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA) - Animal models as a proof of concept
ASIA syndrome, 'Autoimmune (Auto-inflammatory) Syndromes Induced by Adjuvants' includes at least four conditions which share a similar complex of signs and symptoms and have been defined by hyperactive immune responses: siliconosis, macrophagic myofasciitis syndrome, Gulf war syndrome and post-vaccination phenomena. Exposure to adjuvants has been documented in these four medical conditions, suggesting that the common denominator to these syndromes is a trigger entailing adjuvant activity. An important role of animal models in proving the ASIA concept has been established. Experimentally animal models of autoimmune diseases induced by adjuvants are currently widely used to understand the mechanisms and etiology and pathogenesis of these diseases and might thus promote the development of new diagnostic, predictive and therapeutic methods. In the current review we wish to unveil the variety of ASIA animal models associated with systemic and organ specific autoimmune diseases induced by adjuvants. We included in this review animal models for rheumatoid arthritis-like disease, for systemic lupus erythematosus-like disease, autoimmune thyroid disease-like disease, antiphospholipid syndrome, myocarditis and others. All these models support the concept of ASIA, as the Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants. Β© 2013 Bentham Science Publishers
ΠΠΈΠΏΠ΅ΡΡΡΠΈΠΌΡΠ»ΡΡΠΈΡ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΊΠ°ΠΊ ΠΏΡΠΈΡΠΈΠ½Π° Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
The pathogenesis of autoimmune diseases is very complex and multi-factorial. The concept of Mosaics of Autoimmunity was introduced to the scientific community 30 years ago by Y. Shoenfeld and D.A. Isenberg, and since then new tiles to the puzzle are continuously added. This concept specifies general pathological ideas about the multifactorial threshold model for polygenic inheritance with a threshold effect by the action of a number of external causal factors as applied to the field of autoimmunology. Among the external factors that can excessively stimulate the immune system, contributing to the development of autoimmune reactions, researchers are particularly interested in chemical substances, which are widely used in pharmacology and medicine. In this review we highlight the autoimmune dynamics i.e. a multistep pathogenesis of autoimmune diseases and the subsequent development of lymphoma in some cases. In this context several issues are addressed namely, genetic basis of autoimmunity; environmental immunostimulatory risk factors; gene/environmental interaction; pre-clinical autoimmunity with the presence of autoantibodies; and the mechanisms, underlying lymphomagenesis in autoimmune pathology. We believe that understanding the common model of the pathogenesis of autoimmune diseases is the first step to their successful management.ΠΡΡΠΎΠΈΠΌΠΌΡΠ½ΠΎΠΏΠ°ΡΠΈΠΈ ΡΠ²Π»ΡΡΡΡΡ ΠΌΡΠ»ΡΡΠΈΡΠ°ΠΊΡΠΎΡΠΈΠ°Π»ΡΠ½ΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ ΡΠΎ ΡΠ»ΠΎΠΆΠ½ΡΠΌ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·ΠΎΠΌ. ΠΠΎΠ½ΡΡΠΈΠ΅ ΠΌΠΎΠ·Π°ΠΈΠΊΠ° Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ°, ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠΈΠ·ΠΈΡΡΡΡΠ΅Π΅ ΠΎΠ±ΡΠ΅ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ ΠΊΠΎΠ½ΡΠ΅ΠΏΡΠΈΠΈ Π°Π΄Π΄ΠΈΡΠΈΠ²Π½ΠΎ-ΠΏΠΎΠ»ΠΈΠ³Π΅Π½Π½ΠΎΠ³ΠΎ Π½Π°ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Ρ ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΡΠΌ ΡΡΡΠ΅ΠΊΡΠΎΠΌ ΠΏΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΡΠ΄Π° Π²Π½Π΅ΡΠ½ΠΈΡ
ΠΏΡΠΈΡΠΈΠ½Π½ΡΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ², ΠΏΡΠΈΠΌΠ΅Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΊ ΡΡΠ΅ΡΠ΅ Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π±ΡΠ»ΠΎ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΎ Π½Π°ΡΡΠ½ΠΎΠΌΡ ΡΠΎΠΎΠ±ΡΠ΅ΡΡΠ²Ρ 30 Π»Π΅Ρ Π½Π°Π·Π°Π΄ Π. Π¨Π΅Π½ΡΠ΅Π»ΡΠ΄ΠΎΠΌ ΠΈ Π.Π. ΠΠΉΠ·Π΅Π½Π±Π΅ΡΠ³ΠΎΠΌ. Π‘ ΡΠ΅Ρ
ΠΏΠΎΡ ΠΊ ΠΌΠΎΠ·Π°ΠΈΠΊΠ΅ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎ Π΄ΠΎΠ±Π°Π²Π»ΡΡΡΡΡ Π½ΠΎΠ²ΡΠ΅ ΡΠ»Π΅ΠΌΠ΅Π½ΡΡ. Π‘ΡΠ΅Π΄ΠΈ Π²Π½Π΅ΡΠ½ΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ², ΡΠΏΠΎΡΠΎΠ±Π½ΡΡ
ΠΈΠ·Π±ΡΡΠΎΡΠ½ΠΎ ΡΡΠΈΠΌΡΠ»ΠΈΡΠΎΠ²Π°ΡΡ ΠΈΠΌΠΌΡΠ½Π½ΡΡ ΡΠΈΡΡΠ΅ΠΌΡ, Π²Π½ΠΎΡΡ ΡΠ²ΠΎΠΉ Π²ΠΊΠ»Π°Π΄ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ, ΠΎΡΠΎΠ±ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΡΠΈΠ²Π»Π΅ΠΊΠ°ΡΡ Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π²Π΅ΡΠ΅ΡΡΠ²Π°, ΡΠΈΡΠΎΠΊΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΠ΅ Π² ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π΅. Π Π΄Π°Π½Π½ΠΎΠΌ ΠΎΠ±Π·ΠΎΡΠ΅ ΠΎΡΠ²Π΅ΡΠ΅Π½Π° Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Ρ.Π΅. ΠΈΡ
ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π· ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΡΡΡ ΠΊΠ°ΠΊ ΠΌΠ½ΠΎΠ³ΠΎΡΡΠ°ΠΏΠ½ΡΠΉ ΠΏΡΠΎΡΠ΅ΡΡ, Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΡΠ°ΠΊΠΆΠ΅ ΡΡΠ°Π½ΠΎΠ²ΠΈΡΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΠΌ ΠΎΠ±ΡΡΡΠ½ΠΈΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΉ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π»ΠΈΠΌΡΠΎΠΌ ΠΏΡΠΈ Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. ΠΡΠΈ ΠΎΠΏΠΈΡΠ°Π½ΠΈΠΈ ΡΡΠΎΠ³ΠΎ ΠΌΠ½ΠΎΠ³ΠΎΡΡΠ°ΠΏΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΡΠ΄Π΅Π»Π΅Π½ΠΎ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ Π°ΡΠΏΠ΅ΠΊΡΠ°ΠΌ: Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΡΠ½ΠΎΠ²Π° Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ°; ΡΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠΈΠ΅ ΡΠ°ΠΊΡΠΎΡΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½ΠΎΠΏΠ°ΡΠΈΠΉ; Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΡΡΠ΅Π΄ΠΎΠ²ΡΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ²; ΡΡΠ°Π΄ΠΈΡ ΡΡΠ±ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Ρ ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»; ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ, Π»Π΅ΠΆΠ°ΡΠΈΠ΅ Π² ΠΎΡΠ½ΠΎΠ²Π΅ Π»ΠΈΠΌΡΠΎΠΌΠ°Π³Π΅Π½Π΅Π·Π° ΠΏΡΠΈ Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. ΠΡ ΡΡΠΈΡΠ°Π΅ΠΌ, ΡΡΠΎ ΡΠΎΠ·Π΄Π°Π½ΠΈΠ΅ ΠΎΠ±ΡΠ΅ΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΠ΅ΡΠ²ΡΠΌ ΡΠ°Π³ΠΎΠΌ ΠΊ ΠΈΡ
ΡΡΠΏΠ΅ΡΠ½ΠΎΠΌΡ Π»Π΅ΡΠ΅Π½ΠΈΡ
- β¦